IRX-3 is the novel combination of IRX-2 and an immunostimulatory peptide. Pre-clinical studies indicate that the synergy between IRX-2 and this protein enhances T cell maturation and differentiation. IRX-3 is our leading candidate for a combination therapy intended for patients with severe immune suppression.

Although there is an array of potential applications for this therapy, IRX foresees the best marketing opportunities for IRX-3 in the treatment of HIV/AIDS, HPV, Hepatitis B+C, and as a supportive care for cancer patients post-radiation or post-chemotherapy.